Ireland - English - HPRA (Health Products Regulatory Authority)

eco animal health europe limited - ivermectin - oral powder - 6 milligram(s)/gram - ivermectin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - chlortetracycline hydrochloride - oral powder, pre-mix - chlortetracycline hydrochloride antibiotic active 950.0 mg/g - antibiotic & related - pigs | poultry | boar | breeders | broiler | chickens | chicks | chooks | day old chicks | gilt | hatchlings | layers | piglet | - bacterial enteritis | coryza | escherichia coli (e. coli) | hexamitiasis | mycoplasmosis | pasteurella spp. | pneumonia | salmonella | secondary infection | staphylococcus spp. | bacterial pneumonia | including b-lactamase producin | infectious coryza | mycoplasma gallisepticum | pasterellosis | pasteurellosis | post-weaning bacterial enterit | salmonellosis | secondary bacterial infections | secondary bacterial invaders | secondary infection to virus | staphylococcosis

Ireland - English - HPRA (Health Products Regulatory Authority)

eco animal health europe limited - ivermectin - pour-on solution - 5 milligram(s)/millilitre - ivermectin

Ireland - English - HPRA (Health Products Regulatory Authority)

eco animal health europe limited - ivermectin - pour-on solution - 5 milligram(s)/millilitre - ivermectin

Ireland - English - HPRA (Health Products Regulatory Authority)

eco animal health europe limited - ivermectin - pour-on solution - 5 milligram(s)/millilitre - ivermectin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zagro animal health pte ltd - diazinon; liquid hydrocarbon - topical solution/suspension - diazinon organophosphorus active 200.0 g/l; liquid hydrocarbon solvent other 552.0 g/l - parasiticides - animal structure | cattle | goat | horse | kennel, animal living area pest control | pigs | barn | beef | billy | boar | bos ind - buffalo fly | bush fly | cat flea | cattle biting louse | common goat louse | common housefly | dog flea | goatsucking louse | horsebiting louse | horsesucking louse | longnosed cattle louse | pig louse | sarcoptic mange scabies mite | stable fly | cattlebiting louse | damalinia bovis (old name) | house fly | long-nosed sucking louse | werneckiella equi

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - precose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. precose is contraindicated in patients with known hypersensitivity to the drug. precose is contraindicated in patients with diabetic ketoacidosis or cirrhosis. precose is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, precose is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - thrombin alfa (unii: sck81amr7r) (thrombin alfa - unii:sck81amr7r) - recothrom thrombin topical (recombinant), is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age. recothrom may be used in conjunction with an absorbable gelatin sponge, usp. risk summary there are no available data regarding recothrom thrombin topical (recombinant) in pregnant women. no animal reproductive and developmental toxicity studies have been conducted with recothrom. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the presence of recothrom thrombin topical (recombinant) in human milk, the effects on the breastfed infant, and the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for recothrom and any potential adverse effects on the breastfed child from recothrom or from underlying maternal condition. a total of 30 pediatric patients, ages 0 to 16 years (one month to 2 years, n=10; 2 to 12 years, n=12; 12 to 16 years, n=8), were treated in clinical trials with recothrom thrombin topical (recombinant) using a spray applicator to burn wound excision sites prior to autologous skin grafting. no patient experienced a thromboembolic adverse reaction. the safety of recothrom in pediatric patients greater than or equal to one month of age is supported by these data and by extrapolation of efficacy from adequate and well-controlled studies of recothrom in adults. safety and efficacy have not been established in neonates [see adverse reactions (6)] . of 644 patients in clinical studies of recothrom thrombin topical (recombinant), 36% (n=232/644) were ≥65 years old and 15% (n=95/644) were ≥75 years old. no differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

United States - English - NLM (National Library of Medicine)

siga technologies, inc. - tecovirimat (unii: f925rr824r) (tecovirimat - unii:f925rr824r) - tpoxx® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 kg. the effectiveness of tpoxx for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical [see clinical studies (14)] . tpoxx efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models. tpoxx capsules: none. tpoxx injection: the excipient hydroxypropyl-β-cyclodextrin is eliminated through glomerular filtration. therefore, tpoxx injection is contraindicated in patients with severe renal impairment (defined as creatinine clearance below 30 ml/min) [see warnings and precautions (5.2) and use in specific populations (8.6)] . risk summary there are no available data on the use of tecovirimat in pregnant individuals to evaluate for a

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - pradofloxacin (unii: 6o0t5e048i) (pradofloxacin - unii:6o0t5e048i) - pradofloxacin 25 mg in 1 ml - veraflox is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of pasteurella multocida, streptococcus canis, staphylococcus aureus, staphylococcus felis, and staphylococcus pseudintermedius. do not use in dogs. pradofloxacin has been shown to cause bone marrow suppression in dogs. dogs may be particularly sensitive to this effect, potentially resulting in severe thrombocytopenia and neutropenia. quinolone-class drugs have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. pradofloxacin is contraindicated in cats with a known hypersensitivity to quinolones.